6365 results for "11+1双色球多少钱一注"

in 10.15 milliseconds.

• Array_FL_dataset_7

  CN/LOH-profile of Translocation-negative FL_7

  Dataset EGAD00010001241

• Array_FL_dataset_11

  CN/LOH-profile of Translocation-negative FL_11

  Dataset EGAD00010001235

• Array_FL_dataset_5

  CN/LOH-profile of Translocation-negative FL_5

  Dataset EGAD00010001233

• Array_FL_dataset_2

  CN/LOH-profile of Translocation-negative FL_2

  Dataset EGAD00010001238

• Array_FL_dataset_1

  CN/LOH-profile of Translocation-negative FL_1

  Dataset EGAD00010001240

• Array_FL_dataset_9

  CN/LOH-profile of Translocation-negative FL_9

  Dataset EGAD00010001234

• Array_FL_dataset_4

  CN/LOH-profile of Translocation-negative FL_4

  Dataset EGAD00010001236

• Array_FL_dataset_10

  CN/LOH-profile of Translocation-negative FL_10

  Dataset EGAD00010001237

• REL-2017-07-2020

  HipSci - Hereditary Cerebellar Ataxias - Expression Array - July 2017

  Dataset EGAD00010001368

• REL-2017-07-2027

  HipSci - Primary Immune Deficiency - Expression Array - July 2017

  Dataset EGAD00010001382

• REL-2017-07-2021

  HipSci - Hereditary Spastic Paraplegia - Expression Array - July 2017

  Dataset EGAD00010001370

• REL-2017-07-1276

  HipSci - Bardet-Biedl Syndrome - Expression Array - July 2017

  Dataset EGAD00010001340

• Medulloblastoma Cirlce-Seq

  Circle-Seq experiment.

  Dataset EGAD00001009483

• HC_genotyping

  HC genotyping data for lead SNPs using Illuminia Global Array V2.0

  Dataset EGAD00010002475

• CyclomicsSeq_IMCISION_Flongle

  Contains IMCISION samples sequenced on Flongle flowcells

  Dataset EGAD00001010148

• SF10328

  Unknown

  Dataset EGAD00001008303

• Lifelines-CH: processed somatic variant calls

  Processed somatic variant calls

  Dataset EGAD00001010144

• Sample sheet

  Linking anonymized sample IDs and anonymized patient IDs.

  Dataset EGAD00001011166

• Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Lipidomics Study

  The GOLDN study was initiated to assess how genetic factors interact with environmental (diet and drug) interventions to influence blood levels of triglycerides and other atherogenic lipid species and inflammation markers (registered at clinicaltrails.gov, number NCT00083369). The study recruited Caucasian participants primarily from three-generational pedigrees from two NHLBI Family Heart Study (FHS) field centers (Minneapolis, MN and Salt Lake City, UT). Only families with at least two siblings were recruited and only participants who did not take lipid-lowering agents (pharmaceuticals or nutraceuticals) for at least 4 weeks prior to the initial visit were included. A total of 1048 GOLDN participants were included in the diet intervention. The diet intervention followed the protocol of Patsch et al. (1992). The whipping cream (83% fat) meal had 700 Calories/m2 body surface area (2.93 MJ/m2 body surface area): 3% of calories were derived from protein (instant nonfat dry milk) and 14% from carbohydrate (sugar). The ratio of polyunsaturated to saturated fat was 0.06 and the cholesterol content of the average meal was 240 mg. The mixture was blended with ice and flavorings. Blood samples were drawn immediately before (fasting) and at 3.5 and 6 hours after consuming the high-fat meal. For the GOLDN lipidomics study, sterols and fatty acids were measured from stored plasma (-80 degrees Celsius) collected at fasting and 3.5 hours after the diet intervention using TrueMass Panels from Lipomics (West Sacramento, CA). A total of 11 sterols were quantified in nmols/gram of sample including total cholesterol, 7-dehydrocholesterol, desmosterol, lanosterol, lathasterol, cholestanol, coprostanol, beta-sitosterol, campesterol, stigmasterol, and 7alpha-hydroxycholesterol. A total of 35 fatty acids were quantified in nmols/gram of sample inlcuding myristic acid (14:0); pentadecanoic acid (15:0); palmitic acid (16:0); stearic acid (18:0); arachidic acid (20:0); behenic acid (22:0); lignoceric acid (24:0); myristoleic acid (14:1n5); palmitoleic acid (16:1n7); palmitelaidic acid (t16:1n7); oleic acid (18:1n9); elaidic acid (t18:1n9); vaccenic acid (18:1n7); linoleic acid (18:2n6); gamma-linolenic acid (18:3n6); alpha-linolenic acid (18:3n3); stearidonic acid (18:4n3); eicosenoic acid (20:1n9); eicosadienoic acid (20:2n6); mead acid (20:3n9); di-homo-gamma-linolenic acid (20:3n6); arachidonic acid (20:4n6); eicsoatetraenoic acid (20:4n3); eicosapentaenoic acid (20:5n3); erucic acid (22:1n9); docosadienoic acid (22:2n6); adrenic acid (22:4n6); docosapentaenoic acid (22:5n6); docosapentaenoic acid (22:5n3); docosahexaenoic acid (22:6n3); nervonic acid (24:1n9); and plasmalogen derivatives of 16:0, 18:0, 18:1n9, and 18:1n7.

  Study phs000741

• ATAC-seq of a selected group of AML cases

  ATAC-seq data were generated for a number of selected patients to investigate changes in enhancer and promoter regions. ATAC-seq was essentially carried out as described in31. Briefly, prior to transposition the viability of the cells was assessed and 1 × 106 cells were treated in culture medium with DNase I (Sigma) at a final concentration of 200 U ml−1 for 30 minutes at 37 °C. After Dnase I treatment, cells were washed twice with ice-cold PBS, and cell viability and the corresponding cell count were assessed. 5 × 104 cells were aliquoted into a new tube and spun down at 500 × g for 5 minutes at 4 °C, before the supernatant was discarded completely. The cell pellet was resuspended in 50 µl of ATAC-RSB buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2) containing 0.1% NP-40, 0.1% Tween-20, and 1% Digitonin (Promega), and was incubated on ice for 3 minutes to lyse the cells. Lysis was washed out with 1 ml of ATAC-RSB buffer containing 0.1% Tween-20. Nuclei were pelleted at 500 × g for 10 minutes at 4 °C. The supernatant was discarded carefully and the cell pellet was resuspended in 50 µl of transposition mixture (25 µl 2× tagment DNA buffer, 2.5 µl transposase (100 nM final; Illumina), 16.5 µl PBS, 0.5 µl 1% digitonin, 0.5 µl 10% Tween-20, 5 µl H2O) by pipetting up and down six times. The reaction was incubated at 37 °C for 30 minutes with mixing before the DNA was purified using the Monarch PCR & DNA Cleanup Kit (NEB) according to the manufacturer’s instructions. Purified DNA was eluted in 20 µl elution buffer (EB) and 10 µl purified sample was objected to a ten-cycle PCR amplification using Nextera i7- and i5-index primers (Illumina). Purification and size selection of the amplified DNA were carried out with Agencourt AMPure XP beads. For purification the ratio of sample to beads was set to 1:1.8, whereas for size selection the ratio was set to 1:0.55. Purified samples were eluted in 15 µl of EB. Quality and concentration of the generated ATAC libraries were analyzed using the High Sensitivity D1000 ScreenTape Kit (Agilent) and libraries were sequenced paired-end on a NovaSeq (Illumina). ATAC-seq reads were aligned to the human reference genome build hg19 with bowtie2

  Dataset EGAD00001007583

• EGAD00010000654

  Control samples using SNP 6.0 Arrays

  Dataset EGAD00010000654

• EGAD00010000656

  Case samples using SNP 6.0 Array

  Dataset EGAD00010000656

• EGAD00010000668

  Purified plasma cells from bone marrow of Monoclonal gammopathy of unknown significance patient

  Dataset EGAD00010000668

• Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients

  Dataset EGAD00001001275

• Hi-C NTERA-2

  TGCT - GWAS loci Hi-C data

  Dataset EGAD00010001249